You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(688235.SH):國家藥監局批准百澤安®用於食管鱗狀細胞癌的二線治療

格隆匯4月15日丨百濟神州(688235.SH)宣佈,國家藥監局已於近日批准公司核心產品百澤安®(替雷利珠單抗注射液)用於治療既往接受過一線標準化療後進展或不可耐受的局部晚期或轉移性食管鱗狀細胞癌(ESCC)患者。

百澤安®的此次獲批是基於一項隨機、開放性、多中心的全球3期臨牀試驗RATIONALE 302(NCT03430843)的研究結果。該試驗旨在評估百澤安®對比化療,作為局部晚期或轉移性ESCC患者二線治療方案的有效性和安全性。

此次獲批是百澤安®在中國獲得的第八項新適應症批准,有望進一步提升該藥物的可及性。百澤安®擁有廣泛的全球臨牀開發項目,包括17項3期臨牀試驗和4項關鍵性2期臨牀試驗,該等試驗正在為其有效性和安全性提供越來越多的臨牀證據,並在多種癌症類型中確立其治療的影響力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account